AzTrials
AzTrials

Diabetes MellitusNCT03034759

A New Wizard for Insulin Sensitivity Estimation From SAP: a Randomized Controlled Trial in Adolescents With T1D

A study testing individualized insulin sensitivity index (ISind) in people with Diabetes Mellitus, run by Yale University at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

We aim to test the efficacy of a new method for determining individual insulin sensitivity (IS) based on sensor-augmented-insulin pump (SAP) data in order to customize the insulin to carbohydrate ratio (CR) in adolescents with type 1 diabetes (T1D). Read more about this study

Who is it for?
Ages 12 to 21 years
Conditions the study is for
Diabetes Mellitus
What is being tested?
individualized insulin sensitivity index (ISind)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteUnited States
Study dates
1 Oct 2019to 1 Dec 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 to 21 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Age 12-21 year old.
  • Clinical diagnosis of T1D ≥1 year
  • Treatment with sensor augmented pump therapy (insulin pump + glucose sensor) for at least 1 month
  • HbA1c <10%
  • Be able to comprehend written and spoken English

Who cannot join

  • Pregnancy, breast feeding, or plans to get pregnant for the next 12 months
  • On medications that affect insulin sensitivity; has other medical conditions known to affect insulin sensitivity;
  • Cognitive impairment

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Yale Pediatric Diabetes Research Program

    New Haven, Connecticut, 06511

Other trials in United States

About this study

We aim to test the efficacy of a new method for determining individual insulin sensitivity (IS) based on sensor-augmented-insulin pump (SAP) data in order to customize the insulin to carbohydrate ratio (CR) in adolescents with type 1 diabetes (T1D).

To date, the individual insulin sensitivity (IS) could only be investigated by intensive and invasive research techniques that are not feasible to perform in an outpatient setting for pediatric patients with diabetes.

Read more

Recently published studies have demonstrated the efficacy of an algorithm to calculate the patient specific insulin sensitivity to customize the CR for adult patients with T1D. The algorithm has been validated in adult patients, however not yet investigated in the pediatric population with T1D.

The aims of our study are:

  1. to customize the CR of pediatric subjects with T1D using the individualized insulin sensitivity index (ISind) to improve post-prandial blood glucose control after a standard meal.
  2. to test, under free living condition (at home), the efficacy of the customized CR in improving post-prandial glycemic control for pediatric subjects with T1D.

This approach would have at least two potential benefits for pediatric patients with T1D:

  1. To provide a non-invasive tool for individualizing their home insulin therapy;
  2. To offer a reliable instrument for adjusting the meal bolus of the current hybrid closed loop (HCL) systems to account for the inter-subject variability in insulin action.
Read the detailed description

A new method to assess insulin sensitivity (IS) has been proposed and investigated by the PI and his group at the University of Padova. The new insulin sensitivity index, named "SISP" is calculated from data derived from insulin pump and continuous glucose monitoring (CGM) uploads. The efficiency of the SISP has been tested in-silico using the University of Virginia/Padova T1D simulator by mimicking a single-meal scenario with patient-specific optimized carbohydrate ratio (CR) (increased or decreased by 20%) and optimal CR. In all the simulations the use of the optimal CR, calculated with the proposed method, has improved the overall glycemic control. The simulator (S2013) used for this purpose has been valdated and is approved by the FDA as a substitute for preclinical trials for insulin treatments, including closed-loop algorithms. It is comprised of data from 100 in-silico patients that represent the biological variability of a generic real diabetic population. Thus, an algorithm that is tuned on the basis of in-silico analysis can be safely implemented in real-life setting.

The method to estimate SISP and to optimize the CR from SAP data, could be easily applied to the daily management of patients with T1D and in a closed-loop context since several closed-loop algorithms, currently used in clinical trials, are based on the pre-programmed open-loop insulin therapy.

Once the individualized SISP is calculated, it can be used to customize the CR using the in-silico tested algorithm to determine an individualized CR (CRIND).

Consequently, the CRIND can be tested in outpatient setting safely, and adjusted in a run-to-run framework, using a well described approach of self-learning, the latter allowing titration of the insulin therapy based on CGM data using a self-learning algorithm as previously described.

  • Phase 1: "Control period". This phase represents the control frame-time, during which patients, once enrolled, will use their SAP without any adjustment of the CR and correction factors, according to the parameters recorded at the screening visit. This phase is aimed to record the CGM data and will represent the control period of the study. It lasts 3 weeks.
  • Phase 2: "Build-up period" This phase is aimed to obtain an adequate amount of data for customizing the insulin pump parameters to the specific features of each subject according to the proposed algorithms. It consists of three standardized meals (Figure 2) and a run-in phase.

Subjects will be randomly assigned to two different pre-meal insulin CR groups in a 1:1 ratio to determine parameters that will be used to adjust the IS algorithm for pediatric patients with T1D. The post-prandial blood glucose pattern after a pre-meal bolus of CR, CR 20% increased, CR 20% decreased are validated parameters necessary to customize the algorithm for a specific patient population with T1D, therefore subjects will be challenged with two different CRs, depending on the randomization, to collect sufficient data to fine tune the algorithm.

Each subject will go through three meal studies;

Group 1. Meal 1: CR with 20% increase; Meal 2: CR home; Meal 3: CR individualized Group 2. Meal 1: CR with 20% decrease; Meal 2: CR home; Meal 3:CR individualized

  • Before the 1st meal subjects will be randomly assigned to receive a modified premeal bolus (increased or decreased of 20%, CR+/-20%) in a 1:1 ratio. This change of the home CR (CRHOME) will allow us to estimate the accuracy and error of the CRHOME and to calculate, according to the described algorithm ((21) and below), the optimized CR (CRIND). This latter will be tested in both groups as third meal at home.
  • The three meals are followed by a 7 day- run-in period necessary to collect a minimum amount of CGM data to run the algorithm calculations used in the intervention phase. During this period subjects will adopt the CRIND obtained after the standard meals.
  • Phase 3: "Intervention period". This phase is aimed to test the efficacy of the CRIND on mitigating post-prandial hyperglycemia by a home-based study, using periodical adjustment of CR and basal rate according to the "run-to-run" approach. It consists of a self-learning algorithm method to adjust insulin regimen (the basal rate and the CRIND) based on CGM post-meal blood glucose patterns and pre-meal insulin bolus.

Subjects will use the SAP tuned according to the individualized ISR2R and CRR2R obtained from the run-in period, along with an individualized insulin basal rate (BasalR2R). During the run-to-run period subjects will receive weekly revised parameters based on run-to-run algorithm according to data analysis of the past seven days. It will last 3 weeks.

Being tested
individualized insulin sensitivity index (ISind)
Keywords
continuous glucose monitoring
Medical subject headings
Diabetes Mellitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • individualized insulin sensitivity index (ISind)Other

    The new insulin sensitivity index, named "SISP" is calculated from data derived from insulin pump and glucose monitoring (CGM) uploads.

Study groups in NCT03034759
Study groupRoleWhat they receive
All participantsExperimental+Pediatric patients with T1D. All comparisons will be made within group pre and post intervention.
Receives: Other: individualized insulin sensitivity index (ISind)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. overall time in target (70-180mg/dl)

    the percentage of time in target will be calculated "(time in target/total time of records using continuous glucose monitoring)*100.

    Measured: 4 weeks

Secondary outcomes (34)
  1. median percentage of time spent in hypoglycemia (<70mg/dl) during control period

    the percentage of time in target will be calculated "(time in target/total time of records using continuous glucose monitoring)*100.

    Measured: 4 weeks

  2. median percentage of time spent in hypoglycemia (<70mg/dl) post meal 1

    time in target/180 mins * 100

    Measured: 180 minutes post meal

  3. median percentage of time spent in hypoglycemia (<70mg/dl) post meal 2

    time in target/180 mins * 100

    Measured: 180 minutes post meal

  4. median percentage of time spent in hypoglycemia (<70mg/dl) post meal 3

    time in target/180 mins * 100

    Measured: 180 minutes post meal

  5. median percentage of time spent in hypoglycemia (<70mg/dl) during Intervention phase

    the percentage of time in target will be calculated "(time in target/total time of records using continuous glucose monitoring)*100.

    Measured: 4 weeks

  6. overall time in target (70-180mg/dl) after meal 1

    time in target/180 mins * 100

    Measured: 180 minutes post meal

  7. overall time in target (70-180mg/dl) after meal 2

    time in target/180 mins * 100

    Measured: 180 minutes post meal

  8. overall time in target (70-180mg/dl) after meal 3

    time in target/180 mins * 100

    Measured: 180 minutes post meal

  9. overall time in target (70-180mg/dl) during Intervention phase

    the percentage of time in target will be calculated "(time in target/total time of records using continuous glucose monitoring)*100.

    Measured: 4 weeks

  10. median percentage of time in hyperglycemia (>180mg/dl) during Control Phase

    time in target/total time of records using continuous glucose monitoring)*100

    Measured: 4 weeks

  11. median percentage of time in hyperglycemia (>180mg/dl) after meal 1

    time in target/180 mins * 100

    Measured: 180 minutes post meal

  12. median percentage of time in hyperglycemia (>180mg/dl) after meal 2

    time in target/180 mins * 100

    Measured: 180 minutes post meal

  13. median percentage of time in hyperglycemia (>180mg/dl)after meal 3

    time in target/180 mins * 100

    Measured: 180 minutes post meal

  14. median percentage of time in hyperglycemia (>180mg/dl) during intervention phase

    time in target/total time of records using continuous glucose monitoring)*100

    Measured: 4 weeks

  15. median percentage of time below 50mg/dl during control phase

    time in target/total time of records using continuous glucose monitoring)*100

    Measured: 4 weeks

  16. median percentage of time below 50mg/dl after meal 1

    time in target/180 mins * 100

    Measured: 180 minutes post meal

  17. median percentage of time below 50mg/dl after meal 2

    time in target/180 mins * 100

    Measured: 180 minutes post meal

  18. median percentage of time below 50mg/dl after meal 3

    time in target/180 mins * 100

    Measured: 180 minutes post meal

  19. median percentage of time below 50mg/dl during intervention phase

    time in target/total time of records using continuous glucose monitoring)*100

    Measured: 4 weeks

  20. severe hypoglycemic events during control phase

    They will be measured as number of events per person during the weeks of Control Phase

    Measured: 4 weeks

  21. severe hypoglycemic events after meal 1

    They will be measured as number of events per person after meal 1 for the entire day

    Measured: up to 24 hours

  22. severe hypoglycemic events after meal 2

    They will be measured as number of events per person after meal 2 for the entire day

    Measured: up to 24 hours

  23. severe hypoglycemic events after meal 3

    They will be measured as number of events per person after meal 3 for the entire day

    Measured: up to 24 hours

  24. severe hypoglycemic events during intervention phase

    They will be measured as number of events per person during the weeks of Intervention Phase.

    Measured: 4 weeks

  25. active hypoglycemia correction (carbohydrate intake) during control phase

    total number of active events per person during the weeks of Control Phase

    Measured: 4 weeks

  26. active hypoglycemia correction (carbohydrate intake) after meal 1

    total number of active events per person after meal 1 all day

    Measured: up to 24 hours

  27. active hypoglycemia correction (carbohydrate intake) after meal 2

    total number of active events per person after meal 2 all day

    Measured: up to 24 hours

  28. active hypoglycemia correction (carbohydrate intake) after meal 3

    total number of active events per person after meal 3 all day

    Measured: up to 23 hours

  29. active hypoglycemia correction (carbohydrate intake) during intervention phase

    total number of active events per person during the weeks of Intervention Phase

    Measured: 4 weeks

  30. corrective bolus after meal during control phase

    total number of active events per person during the weeks of Control Phase vs Intervention Phase

    Measured: 4 weeks

  31. corrective bolus after meal 1

    total number of active events per person after meal 1 for the entire day

    Measured: up to 24 hours

  32. corrective bolus after meal after meal 2

    total number of active events per person after meal 2 for the entire day

    Measured: up to 24 hours

  33. corrective bolus after meal after meal 3

    total number of active events per person after meal 3 for the entire day

    Measured: up to 24 hours

  34. corrective bolus after meal during intervention phase

    total number of active events per person during the weeks of Intervention Phase

    Measured: 4 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jan 2017 (estimated)
  2. Study start1 Oct 2019 (estimated)
  3. Primary completion1 Jan 2020 (estimated)
  4. Study completion1 Dec 2022 (estimated)

Why it stopped: Investigator has moved to another institution

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03034759
Sponsor's protocol ID
1611018615
Status last verified
Jul 2019
First submitted
24 Jan 2017
Last updated
11 Jul 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing individualized insulin sensitivity index (ISind) in people with Diabetes Mellitus, run by Yale University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 11 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

overall time in target (70-180mg/dl) (time frame: 4 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in